共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 基于中西药理比较的蒲黄生物活性成分分析显示文摘通过对中药蒲黄与西药菠萝蛋白酶药理的比较,分析认为蒲黄与菠萝蛋白酶药理作用基本相同,蒲黄中具有活血化瘀药效的生物活性成分是能被消化道完整吸收的具有纤维蛋白溶解活性的蛋白酶,同时指出了蒲黄药用中存在的问题、注意事项及未来的研究方向. | 施如枫 于瑞雪 白现广 | 2017 | 曲靖师范学院学报2017，36，6： | 5 |
| 2 | Bromelain and Cardiovascular Risk Factors in Diabetes:An Exploratory Randomized,Placebo Controlled,Double Blind Clinical Trial显示文摘Objective: To assess whether the dietary supplement(bromelain) has the potential to reduce plasma fibrinogen and other cardiovascular disease(CVD) risk factors in patients with diabetes. Methods: This randomized placebo controlled, double blind, parallel design, efficacy study was carried out in China and investigated the effect of 12 weeks of bromelain(1,050 mg/day) on plasma fibrinogen. This randomized controlled trial(RCT) recruited 68 Chinese diabetic patients [32 males and 36 females; Han origin, mean age of 61.26 years(standard deviation(SD), 12.62 years)] with at least one CVD risk factor. Patients were randomized into either bromelain or placebo group. While bromelain group received bromelain capsule, the placebo group received placebo capsule which consisted inert ingredient and has no treatment effect. Subjects were required to take 1,050 mg(3×350 mg) of either bromelain or starch-filled placebo capsules, two to be taken(2×350 mg) after breakfast and another(350 mg) after dinner, daily for 12 weeks. Plasma fibrinogen, CVD risk factors and anthropometric indicators were determined at baseline and at 12 weeks. Results: The change in the fibrinogen level in the bromelain group at the end of the study showed a mean reduction of 0.13 g/L(standard deviation(SD) 0.86g/L) compared with the mean reduction of 0.36 g/L(SD 0.96 g/L) for the placebo group. However, there was no significant difference in the mean change in fibrinogen between the placebo and bromelain groups(mean difference=0.23g/L(SD 0.22 g/L), P=0.291). Similarly, the difference in mean change in other CVD risk factors(blood lipids, blood pressure), blood glucose, C-reactive protein and anthropometric measures between the bromelain and placebo groups was also not statistically significant. Statistical differences in fibrinogen between bromelain and placebo groups before the trial despite randomization may have influenced the results of this study. Conclusion: This RCT failed to show a beneficial effect in reducing fibrinogen or influencing other selected CVD risk factors but suggests other avenues for subsequent research on bromelain. | 黎七妹 倪青 廖星 高怀林 Nicola Robinson | 2016 | Chinese Journal of Integrative Medicine2016，22，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员